Table 1.
Baseline Characteristics of Incident Aortic Syndrome Cohort
| Total (N=133) |
Aortic Dissection (N=77) |
IMH (N=21) |
PAU (N=35) |
P |
|
|---|---|---|---|---|---|
|
Age (years, mean, SD) |
71.8 (14.1) | 68.9 (15.6) | 73.5 (11.5) | 77.1 (10.0) | 0.01 |
| Gender (male) | 76 (57.1%) | 46 (59.7%) | 11 (52.4%) | 19 (54.3%) | 0.77 |
| Ethnicity | 0.01 | ||||
| Hispanic/Latino | 2 (1.5%) | 2 (2.6%) | 0 (0.0%) | 0 (0.0%) | |
| Not Hispanic/Latino | 119 (89.5%) | 63 (81.8%) | 21 (100.0%) | 35 (100.0%) | |
| Unknown | 12 (9.0%) | 12 (15.6%) | 0 (0.0%) | 0 (0.0%) | |
| Race | 0.15 | ||||
| White | 115 (86.5%) | 64 (83.1%) | 18 (85.7%) | 33 (94.3%) | |
| Unknown | 11 (8.3%) | 10 (13.0%) | 1 (4.8%) | 0 (0.0%) | |
| African American | 3 (2.3%) | 1 (1.3%) | 1 (4.8%) | 1 (2.9%) | |
| Asian | 3 (2.3%) | 1 (1.3%) | 1 (4.8%) | 1 (2.9%) | |
| Hawaii/Pacific Island | 1 (0.8%) | 1 (1.3%) | 0 (0.0%) | 0 (0.0%) | |
| Acuity of diagnosis | <0.01 | ||||
| Acute | 79 (59.4%) | 52 (67.5%) | 17 (81.0%) | 10 (28.6%) | |
| Subacute | 4 (3.0%) | 2 (2.6%) | 1 (4.8%) | 1 (2.9%) | |
| Chronic | 3 (2.3%) | 2 (2.6%) | 0 (0.0%) | 1 (2.9%) | |
| Unknown | 47 (35.3%) | 21 (27.3%) | 3 (14.3%) | 23 (65.7%) | |
|
Other clinical features at presentation |
|||||
| Malperfusion | 6 (4.5%) | 5 (6.5%) | 1 (4.8%) | 0 (0.0%) | 0.36 |
| Rupture | 12 (9.0%) | 9 (11.7%) | 2 (9.5%) | 1 (2.9%) | 0.36 |
| Coronary Ischemia | 7 (5.3%) | 5 (6.5%) | 2 (9.5%) | 0 (0.0%) | 0.24 |
| Cardiac Tamponade | 10 (7.5%) | 10 (13.0%) | 0 (0.0%) | 0 (0.0%) | 0.02 |
| Aortic Valve Insufficiency |
14 (10.5%) | 14 (18.2%) | 0 (0.0%) | 0 (0.0%) | <0.01 |
|
Blood pressure at presentation |
|||||
| Systolic | 139.2 (33.3) | 136.8 (34.8) | 139.7 (35.3) | 143.6 (29.0) | 0.62 |
| Diastolic | 73.6 (16.8) | 74.6 (19.0) | 71.1 (17.2) | 73.1 (11.6) | 0.70 |
| Shock at presentation | 8 (6.3%) | 7 (9.9%) | 1 (4.8%) | 0 (0.0%) | 0.14 |
| BMI | 27.5 (6.8) | 27.4 (6.7) | 28.8 (7.1) | 26.9 (6.7) | 0.60 |
|
Medications at presentation |
|||||
| Aspirin | 58 (43.6%) | 28 (36.4%) | 12 (57.1%) | 18 (51.4%) | 0.13 |
| Beta blocker | 53 (39.8%) | 28 (36.4%) | 11 (52.4%) | 14 (40.0%) | 0.41 |
| ACEI/ARB | 43 (32.3%) | 21 (27.3%) | 9 (42.9%) | 13 (37.1%) | 0.31 |
| Statin | 42 (31.6%) | 21 (27.3%) | 6 (28.6%) | 15 (42.9%) | 0.25 |
|
Lab values at presentation |
|||||
| Hemoglobin | 12.7 (2.0) | 13.3 (1.9) | 12.1 (1.9) | 12.0 (1.9) | <0.01 |
| Creatinine | 1.3 (1.2) | 1.4 (1.6) | 1.1 (0.3) | 1.2 (0.4) | 0.44 |
| INR | 1.3 (0.6) | 1.3 (0.6) | 1.3 (0.6) | 1.3 (0.6) | 0.96 |
| Platelets | 214.6 (85.6) | 207.7 (69.3) | 220.3 (112.3) | 225.0 (98.2) | 0.61 |
| PTT | 37.0 (34.7) | 31.9 (16.3) | 50.9 (66.4) | 34.1 (14.5) | 0.25 |
| Risk factors | |||||
| Bicuspid Aortic Valve | 3 (2.3%) | 1 (1.3%) | 1 (4.8%) | 1 (2.9%) | 0.38 |
| Aortic Atherosclerosis | 111 (83.5%) | 57 (74.0%) | 20 (95.2%) | 34 (97.1%) | <0.01 |
| Prior Aortic Dilatation | 64 (51.6%) | 36 (50.7%) | 13 (68.4%) | 15 (44.1%) | 0.23 |
| Connective tissue disorder |
8 (6.0%) | 8 (10.4%) | 0 (0.0%) | 0 (0.0%) | 0.18 |
| Iatrogenic | 7 (5.3%) | 6 (7.8%) | 1 (4.8%) | 0 (0.0%) | 0.11 |
| Prior Aortic Surgery | 14 (10.5%) | 8 (10.4%) | 2 (9.5%) | 4 (11.4%) | 0.97 |
| Diagnostic modality | |||||
| ECHO | 15 (11.3%) | 13 (16.9%) | 2 (9.5%) | 0 (0.0%) | 0.01 |
| CT | 105 (78.9%) | 53 (68.8%) | 19 (90.5%) | 33 (94.3%) | <0.02 |
| MRI | 4 (3.0%) | 2 (2.6%) | 0 (0.0%) | 2 (5.7%) | 0.62 |
| Angiography | 3 (2.3%) | 3 (3.9%) | 0 (0.0%) | 0 (0.0%) | .32 |
| Stanford Class | |||||
| A | - | 45 (58.4%) | 5 (23.8%) | - | <.01 |
| B | - | 32 (41.6%) | 16 (76.2%) | - | |
| DeBakey Class | |||||
| I | - | 24 (31.2%) | - | - | |
| II | - | 21 (27.3%) | - | - | |
| IIIa | - | 8 (10.4%) | - | - | |
| IIIb | - | 24 (31.2%) | - | - | |
IMH – intramural hematoma, PAU – penetrating aortic ulcer.